research Alopecia areata following COVID-19 vaccine: a systematic review
Alopecia areata after COVID-19 vaccination is rare but important to recognize for timely treatment.
Search
for
Sort by
Research
180-210 / 1000+ resultsresearch Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon α 2a therapy for chronic hepatitis C virus infection
Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.
research A Comparison of the Efficacy, Relapse Rate and Side Effects among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata
imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
research 151 High effectiveness of tildrakizumab over 52 weeks in patients with or without nail psoriasis: results from the phase IV POSITIVE Austrian subset
Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
research Global and exponential stabilization of a chemotactic alopecia areata model with signal-dependent diffusion and sensitivity
Reducing CD8+ T cell growth can stabilize alopecia areata.
research A case of alopecia areata after rabies vaccination: unreported adverse effect?
Rabies vaccine might cause hair loss due to immune issues.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Answer
Cyclosporine-A can cause excessive hair growth, which usually stops after discontinuing the drug.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research High throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in Alopecia Areata
Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.
research Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options
Allergic reactions to blood thinners are rare but can be serious, requiring careful testing and alternative treatments.
research Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.
research Successful management of therapy-resistant chronic refractory atopic dermatitis and alopecia universalis with oral tofacitinib in a girl
Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
research Tackling Adverse Effects
research Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
research 219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid
Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.
research Phenotypic Analysis of T-Cells in Extensive Alopecia Areata Scalp Suggests Partial Tolerance
T-cells in alopecia areata scalp show abnormal regulation, leading to less inflammation.
research Gastroparesis - a novel cause of persistent thyroid stimulating hormone elevation in hypothyroidism.
Gastroparesis can cause persistent TSH elevation in hypothyroidism despite treatment.
research Psoriatic Alopecia/Alopecia Areata‐Like Reactions Secondary to Anti‐Tumour Necrosis Factor‐Alpha Therapy
Anti-TNF therapy can cause a rare hair loss condition similar to alopecia areata.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research 470 Exploring the possible involvement of skin-resident memory T cells in refractory chronic alopecia areata
Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.
research Post-acute COVID-19 syndrome and its prolonged effects: An updated systematic review
Long-lasting COVID-19 symptoms like fatigue and breathing difficulties can persist for over 60 days, requiring ongoing care.
research 586 Increase in CD8+ effector memory cells re-expressing CD45RA (TEMRA) reflects disease activity and enables early prediction of therapeutic outcome in rapidly progressive alopecia areata
Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
research Skin CD4+ memory T cells exhibit combined cluster-mediated retention and equilibration with the circulation
Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.
research Efficacy of topical diphenylcyclopropenone maintenance treatment for patients with alopecia areata: A retrospective study
Diphenylcyclopropenone treatment helps prevent hair loss relapse in alopecia areata patients.
research Circumscribed Alopecia Areata Incognita and Response to Tofacitinib
Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Supplementary Material for: TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research P6590Androgenic effects on ventricular repolarization: a translational study from pharmacovigilance databases to iPSC-cardiomyocytes
Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.